ReviewCurrent medicinal chemistry2012
Hepatocellular carcinoma: important biomarkers and their significance in molecular diagnostics and therapy.
Review in Current medicinal chemistry, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 28 citations in OpenAlex.
- Function of mitochondrial pyruvate carriers in hepatocellular carcinoma patients.Oncology letters · 2018Article
- SRC-2-mediated coactivation of anti-tumorigenic target genes suppresses MYC-induced liver cancer.PLoS genetics · 2017Article
- Tissue- and Serum-Associated Biomarkers of Hepatocellular Carcinoma.Biomarkers in cancer · 2016Review
- The aberrant overexpression of vimentin is linked to a more aggressive status in tumours of the gastrointestinal tract.Przeglad gastroenterologiczny · 2015Review
- Expression characteristics of KAI1 and vascular endothelial growth factor and their diagnostic value for hepatocellular carcinoma.Gut and liver · 2014Article
- Decorin deficiency promotes hepatic carcinogenesis.Matrix biology : journal of the International Society for Matrix Biology · 2014Article
- Ablation therapy for hepatocellular carcinoma: past, present and future perspectives.Hepatic oncology · 2014Review
- Cyclooxygenase-2 inhibitor is a robust enhancer of anticancer agents against hepatocellular carcinoma multicellular spheroids.OncoTargets and therapy · 2014Article
- RNA interference targeting human integrin α6 suppresses the metastasis potential of hepatocellular carcinoma cells.European journal of medical research · 2013Article
- Personalized oncology in interventional radiology.Journal of vascular and interventional radiology : JVIR · 2013Review
- Inhibition of VEGF expression through blockade of Hif1α and STAT3 signalling mediates the anti-angiogenic effect of melatonin in HepG2 liver cancer cells.British journal of cancer · 2013Article
- Biomarkers for hepatocellular carcinoma: progression in early diagnosis, prognosis, and personalized therapy.Biomarker research · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The increasing incidence of hepatocellular carcinoma (HCC) is of great concern not only in the United States but throughout the world because of two major reasons: firstly, HCC is one of the most lethal form of malignancies with less than 10% survival rate and secondly, a lack of prudent diagnostics makes early detection of HCC nearly impossible. The poor prognosis of HCC accentuates the need to develop new diagnostic markers and therapeutic approaches. In this review we discuss recent advances made in the discovery of molecular biomarkers and their significance in the detection of HCC. We focus on three major classes of biomarkers: serological, tumor, peri-tumoral tissue and cancer stem cell markers. Considerable progress has been made recently in our understanding of HCC at the molecular level increasing the potential of molecular targeted therapy. A number of molecular targets have been identified that have been showing promising results. Of particular interest is Sorafenib, a multi-tyrosine kinase inhibitor that has been approved for the HCC treatment. Inhibitors of other molecular targets such as VEGF, EGFR, mTOR etc. are emerging as plausible therapeutic agents for the treatment of HCC and are discussed in this review.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.